Compare Global X Copper Miners ETF (COPX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Merck & Co., Inc. — how do they compare? Global X Copper Miners ETF trades at $76.32, while Merck & Co., Inc. trades at $123.51 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while Global X Copper Miners ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals.
| COPX | MRK | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $129.52 |
52-Week Low | $42.75 | $77.60 |
Market Cap | — | $298.31B |
Enterprise Value | — | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $74.35, down 2.86% amid bearish technical signals with all 16 moving average indicators signaling sell. The ETF provides exposure to copper mining companies benefiting from AI-driven electrification demand, though key financial ratios remain undisclosed in current data. Recent news highlights copper's structural role in AI infrastructure and energy transition.
Outlook hinges on copper supply-demand dynamics amplified by AI data center expansion, though technical weakness suggests near-term pressure. Risks include commodity price volatility and execution challenges in mining supply chains. Analyst sentiment remains constructive on long-term copper fundamentals despite current bearish technical positioning.
Merck (MRK) trades at $123.485, down 0.44% on the day, with a bullish technical signal and strong institutional accumulation. The company reported solid earnings beats in recent quarters despite a Q1 2026 loss, maintains robust profitability with a 73.91% gross margin and 13.59% net margin, and is actively expanding its oncology pipeline through acquisitions like Terns Pharmaceuticals. Cash flow from operations remains healthy at $16.47B for 2025, supporting strategic investments and shareholder returns.
Outlook remains positive with a $137.30 consensus price target representing 11% upside, supported by 67.57% analyst buy ratings. Key opportunities include pipeline expansion via M&A and sustained profitability, while risks involve integration of acquisitions, patent pressures, and competitive threats in oncology. The stock's valuation at 34.02 P/E appears elevated but justified by growth prospects and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
